{"lastName":"Schmitt","objectUrn":"urn:li:member:572624464","geoRegion":"Bavaria, Germany","fullName":"Saskia Schmitt","firstName":"Saskia","currentPositions":[{"companyName":"Tubulis GmbH","title":"Associate Director Biology","tenureAtCompany":{"numYears":3,"numMonths":5},"companyUrnResolutionResult":{"employeeCountRange":"51-200","headquarters":{"geographicArea":"Bayern","country":"Germany","city":"Munich","postalCode":"81377"},"website":"http:\/\/www.tubulis.com","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/tubulis\/","industry":"Biotechnology Research"},"startedOn":{"month":7,"year":2023},"companyUrn":"urn:li:fs_salesCompany:14776151"}],"entityUrn":"urn:li:fs_salesProfile:(ACwAACIhjlABCZlNzyS4S1ug2V43O5DiQ-ZNM24,NAME_SEARCH,Y8mY)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1600346987182?e=1723075200&v=beta&t=bAXnwJhqFfGAQfJaW-dNu9riK2M1Ms7Mt5zDrqku2ok","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1600346987182?e=1723075200&v=beta&t=xN-4qBHk77AyDcflRMC7qqTwUFcFf45d1uW9RgISagw","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1600346987182?e=1723075200&v=beta&t=grbhqB-usWVefLNd99FzGUzKnXUt91aY_FteJDuNRUw","height":400},{"width":800,"fileIdentifyingUrlPathSegment":"800_800\/0\/1600346987182?e=1723075200&v=beta&t=P5ueL6p-JDHH4fkJRFt3e47tULTlAo2Mnj4dUYbGAn4","height":800}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/C4D03AQHhUywDaNHUWw\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{},"industry":"Biotechnology Research","educations":[{"endedOn":{"year":2020},"degree":"Dr.rer.nat.","eduId":423873072,"schoolUrn":"urn:li:fs_salesSchool:596185","school":"urn:li:fs_salesSchool:596185","fieldsOfStudy":["Immunotherapy of Cancer"],"schoolName":"Ludwig-Maximilians Universit\u00e4t M\u00fcnchen","startedOn":{"year":2016}},{"endedOn":{"year":2016},"degree":"Master's degree","eduId":423871681,"schoolUrn":"urn:li:fs_salesSchool:15092565","school":"urn:li:fs_salesSchool:15092565","fieldsOfStudy":["Biomedical Sciences"],"schoolName":"Julius-Maximilians-Universit\u00e4t W\u00fcrzburg","startedOn":{"year":2013}},{"endedOn":{"year":2013},"degree":"Bachelor's degree","eduId":423872290,"schoolUrn":"urn:li:fs_salesSchool:15092565","school":"urn:li:fs_salesSchool:15092565","fieldsOfStudy":["Biomedical Sciences"],"schoolName":"Julius-Maximilians-Universit\u00e4t W\u00fcrzburg","startedOn":{"year":2010}},{"endedOn":{"year":2010},"degree":"Abitur","schoolName":"M\u00e4dchenbildungswerk Gem\u00fcnden","startedOn":{"year":2001},"eduId":423870730}],"skills":[{"numOfEndorsement":3,"name":"Life Sciences"},{"numOfEndorsement":3,"name":"Biochemistry"},{"numOfEndorsement":2,"name":"Research"},{"numOfEndorsement":2,"name":"Cell Biology"},{"numOfEndorsement":1,"name":"Cell Culture"},{"numOfEndorsement":1,"name":"Western Blotting"},{"numOfEndorsement":1,"name":"Immunology"},{"numOfEndorsement":0,"name":"Protein Expression"},{"numOfEndorsement":0,"name":"Protein Purification"},{"numOfEndorsement":0,"name":"ELISA"},{"numOfEndorsement":1,"name":"Flow Cytometry"},{"numOfEndorsement":0,"name":"Confocal Microscopy"},{"numOfEndorsement":1,"name":"Assay Development"},{"numOfEndorsement":0,"name":"Functional Assays"},{"numOfEndorsement":1,"name":"Cloning"},{"numOfEndorsement":0,"name":"Protein Analysis and Characterization"},{"numOfEndorsement":0,"name":"Antibody"},{"numOfEndorsement":1,"name":"Antibody Engineering"},{"numOfEndorsement":0,"name":"Cancer Immunotherapy"},{"numOfEndorsement":0,"name":"DC vaccination"}],"numOfConnections":560,"patents":[],"headline":"Associate Director Biology at Tubulis GmbH","courses":[],"certifications":[],"memberBadges":{"premium":false,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/saskia-schmitt-a9492b13b","organizations":[],"location":"Bavaria, Germany","publications":[{"name":"Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting \u03b1CD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells","publishedOn":{"month":11,"day":12,"year":2020},"publisher":"Frontiers in Immunology","url":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.602802\/full","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAACIhjlABCZlNzyS4S1ug2V43O5DiQ-ZNM24,NAME_SEARCH,Y8mY)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABOdXQQBF80VBUhDIwbW-bBrDzCmewGGYhg,NAME_SEARCH,lD7h)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAACumwiYBKhP7Fj54PLRh5KCxJhfYL5SA1l4,NAME_SEARCH,QfpT)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAArkbV8BCvPbqnNTby6S8ocotAMmnrvqj8I,NAME_SEARCH,r9Gv)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAACAn-BYBT9xH-VgSA1O7Qreaj_Oq-a462Mo,NAME_SEARCH,fEFf)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAA-CKOIB-Ei_gsnfM-ziK82zBcVGvI8biAU,NAME_SEARCH,FQHM)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAADcsprMBQu3RGINqU8bb5PjsSgATK0d1SgM,NAME_SEARCH,_X-I)"}]},{"name":"A modular and controllable T cell therapy platform for acute myeloid leukemia","publishedOn":{"month":1,"day":7,"year":2021},"publisher":"Leukemia","url":"https:\/\/www.nature.com\/articles\/s41375-020-01109-w?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+leu%2Frss%2Fcurrent+%28Leukemia+-+Issue%29","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAACIhjlABCZlNzyS4S1ug2V43O5DiQ-ZNM24,NAME_SEARCH,Y8mY)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABFMWwgBcYvDfsI__zPhD4WjsW-NKOuwNag,NAME_SEARCH,HuoW)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAACSvJrIBjXuOPPKDWg1l6y_SolfufMEvXWY,NAME_SEARCH,qWU7)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAACeEyXIBnVUNKXsARRD_Zu-3bVaXxOxTlbQ,NAME_SEARCH,VApe)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAACjwBPABSKICLc20ATl_Gip6lezPRoc49P4,NAME_SEARCH,nxdT)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABjEuaIB0XJBRN0xpSYs2xS8Hnl4jUf7-ik,NAME_SEARCH,pLLS)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD9oyEBpcj0a_n-heU-BqznNuP952sZLFU,NAME_SEARCH,3480)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAACiVAeEBYChm_NL15Ila2xDnLR9NjvfAdhg,NAME_SEARCH,rT-x)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAA-CKOIB-Ei_gsnfM-ziK82zBcVGvI8biAU,NAME_SEARCH,FQHM)"}]},{"name":"SIRP\u03b1-\u03b1CD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells","publishedOn":{"month":9,"day":27,"year":2021},"publisher":"Journal of hematology & oncology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/34579739\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAACIhjlABCZlNzyS4S1ug2V43O5DiQ-ZNM24,NAME_SEARCH,Y8mY)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABOdXQQBF80VBUhDIwbW-bBrDzCmewGGYhg,NAME_SEARCH,lD7h)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAC2FED8B2yWzFwk5E5zfzaiYKV8p2bPtomc,NAME_SEARCH,hJQo)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAyaZZ4BLlkK5JHEWuHLuK5rBO2a7a9OXU0,NAME_SEARCH,Gygx)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABjEuaIB0XJBRN0xpSYs2xS8Hnl4jUf7-ik,NAME_SEARCH,pLLS)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAACjQ2aABUAz50U5kZFdyBMMSfT8uSJ0mlfY,NAME_SEARCH,Jw7U)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAADcsprMBQu3RGINqU8bb5PjsSgATK0d1SgM,NAME_SEARCH,_X-I)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAA-CKOIB-Ei_gsnfM-ziK82zBcVGvI8biAU,NAME_SEARCH,FQHM)"}]},{"name":"TARGETING FLT3 BY NEW-GENERATION ANTIBODY-DRUG-CONJUGATE IN COMBINATION WITH KINASE INHIBITORS FOR TREATMENT OF AML","publishedOn":{"month":8,"day":18,"year":2022},"publisher":"Blood","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAACIhjlABCZlNzyS4S1ug2V43O5DiQ-ZNM24,NAME_SEARCH,Y8mY)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAB276i8BGa8Dxwrvm9c9wn5STZVl82D1SJg,NAME_SEARCH,DvGF)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAClIJlQBMkPkCzHkzGHip4Gbg3BFS5BNXH4,NAME_SEARCH,4OqP)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAACl22_QBLgpM9rgElGfxzgsBlBYpy54I7kU,NAME_SEARCH,e8UA)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABVQMHEBsQX9LJ5Jre6EogF5Mf5ZcUX2RY4,NAME_SEARCH,JD3J)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAACiVAeEBYChm_NL15Ila2xDnLR9NjvfAdhg,NAME_SEARCH,rT-x)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAA-CKOIB-Ei_gsnfM-ziK82zBcVGvI8biAU,NAME_SEARCH,FQHM)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABnluo8BnJoPpbDGDmF5tZG8MeGsgMyzsLw,NAME_SEARCH,qzwc)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABhlDfIBY6TmFSX6LzLBsDfTCTGKLT5Jj5E,NAME_SEARCH,HEHW)"}]},{"name":"Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody\u2013Drug Conjugates","publishedOn":{"month":12,"day":5,"year":2023},"publisher":"Molecular Cancer Therapeutics","url":"https:\/\/aacrjournals.org\/mct\/article\/doi\/10.1158\/1535-7163.MCT-23-0359\/731513\/Design-and-Evaluation-of-Phosphonamidate-Linked","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAACIhjlABCZlNzyS4S1ug2V43O5DiQ-ZNM24,NAME_SEARCH,Y8mY)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAADGIPSwBdH2FTfYRMsicsTErith5YFSx5-U,NAME_SEARCH,sa4h)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAADAvsJIBVZ2Q7YsXWmRA90DonTlEFfDRph4,NAME_SEARCH,wld2)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAACx1up8B8G68-Hg1QE4XOIpmZ8cFdG7j0Qg,NAME_SEARCH,T47i)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAADRJfjkBeGcUuGNghuG7zrGpWllkTQmgOuQ,NAME_SEARCH,ELtv)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAADthZq8Bdc9dqZU4pylS2XCXX38fII9x02Y,NAME_SEARCH,zqe1)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABnluo8BnJoPpbDGDmF5tZG8MeGsgMyzsLw,NAME_SEARCH,qzwc)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABhlDfIBY6TmFSX6LzLBsDfTCTGKLT5Jj5E,NAME_SEARCH,HEHW)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABryle8BsOvCTQ7-1u_Wr7TCJjcWznCIcfM,NAME_SEARCH,_KzC)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAClIJlQBMkPkCzHkzGHip4Gbg3BFS5BNXH4,NAME_SEARCH,4OqP)"}]}],"positions":null,"posts":[{"createdAt":1710411360000,"insightId":"2dab5a21-9dac-44d4-8cca-3dd147154235","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":26},{"type":"PRAISE","count":6}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7173985422681780224","threadUrn":"urn:li:ugcPost:7173985422681780224","reactionsCount":32,"commentsCount":2,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7173985422681780224","message":{"attributes":[{"length":12,"start":16,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:14776151"}}}],"text":"Great news from Tubulis GmbH! The completion of the Series B2 financing round will give us the opportunity to support not only the clinical evaluation of our lead ADC candidates TUB-030 and TUB-040, but also to further expand our pipeline. Happy to be part of the team and to share their vision of delivering the true value of ADCs!"},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"title":{"text":"Series B2"},"mediaType":"PAGINATEDDOCUMENT"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7173981383390904320","message":{"attributes":[{"start":139,"length":10,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:financing"}}},{"start":161,"length":17,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:79163517"}}},{"start":184,"length":14,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:1209545"}}},{"start":245,"length":21,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:78826620"}}},{"start":520,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:adc"}}},{"start":693,"length":11,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:solidtumor"}}},{"start":956,"length":15,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:845275730"}}},{"start":978,"length":16,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:13283147"}}},{"start":1130,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cancers"}}},{"start":1164,"length":22,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/bit.ly\/3IxICOZ"}}}],"text":"Today marks a pivotal moment in the evolution of Tubulis. We have successfully closed an upsized and oversubscribed \u20ac128 million Series B2 #financing co-led by \u200bEQT Life Sciences\u200b and Nextech Invest, with participation from new US-based funds, \u200bFrazier Life Sciences\u200b and Deep Track Capital, as well as all of our existing investors.\n\nThe support of this syndicate of leading global biotech investors underscores the potential of our unique approach to pioneering the next wave of truly differentiated, disease-specific #ADC therapeutics. With this funding, we are well-positioned to advance our next-generation ADCs into clinical evaluation and achieve clinical proof-of-concept for our lead #SolidTumor candidates, TUB-040 and TUB-030. The proceeds will also support the further development of our technology platforms to unlock novel payloads and the establishment of a US subsidiary to expand our corporate footprint.\n\nWe look forward to working with \u200bChristoph Broja\u200b and \u200bKanishka Pothula\u200b as new members of our Supervisory Board to realize our vision of providing new, high-quality treatment options for many hard-to-treat #cancers.\n\nRead the full PR here: https:\/\/bit.ly\/3IxICOZ\n"},"entityUrn":"urn:li:ugcPost:7173981383390904320"},"entityUrn":"urn:li:ugcPost:7173985422681780224"}}}]}